Pralsetinib, sold under the brand name Gavreto, is a medication approved RET mutation-positive medullary thyroid cancer and RET fusion-positive differentiated thyroid cancer refractory to radioactive iodine therapy. Reference standards of Pralsetinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
No Data Found
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
